The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Pharmagreen Biotech's current ratio for the quarter that ended in Jun. 2023 was 0.02.
Pharmagreen Biotech has a current ratio of 0.02. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Pharmagreen Biotech has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.
The historical rank and industry rank for Pharmagreen Biotech's Current Ratio or its related term are showing as below:
PHBI'
s Current Ratio Range Over the Past 10 Years
Min: 0.01 Med: 0.11 Max: 0.22
Current: 0.02
During the past 7 years, Pharmagreen Biotech's highest Current Ratio was 0.22. The lowest was 0.01. And the median was 0.11.
PHBI's Current Ratio is ranked worse than 99.07% of 1073
companies
in the Drug Manufacturers industry
Industry Median: 1.89
vs PHBI: 0.02
Pharmagreen Biotech Current Ratio Historical Data
The historical data trend for Pharmagreen Biotech's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Pharmagreen Biotech's Current Ratio
For the Drug Manufacturers - Specialty & Generic subindustry, Pharmagreen Biotech's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharmagreen Biotech's Current Ratio Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pharmagreen Biotech's Current Ratio distribution charts can be found below:
* The bar in red indicates where Pharmagreen Biotech's Current Ratio falls into.
Pharmagreen Biotech Current Ratio Calculation
The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.
Pharmagreen Biotech's Current Ratio for the fiscal year that ended in Sep. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharmagreen Biotech (OTCPK:PHBI) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Pharmagreen Biotech Current Ratio Related Terms
Thank you for viewing the detailed overview of Pharmagreen Biotech's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Pharmagreen Biotech (Pharmagreen Biotech) Business Description
Pharmagreen Biotech Inc is a biotech science company with specialized products and services in the cannabis industry. The company plans to produce and sell tissue culture plantlets and cannabis oil. Its line of nutraceutical products is a proprietary blend of therapeutic plants and mushrooms. It is developing its business model beyond just cannabis, and is focused on near term revenues from its proprietary blend of therapeutic plants and fungi, a nutraceutical wellness product. Utilizing the Company's expertise in plant genetics, Its transgenic program uses the newest technology available to research and create nutraceuticals, protein-based vaccines, and daily supplements with the potential to improve lives and address a wide variety of disease conditions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PHBI has been successfully added to your 